AdAlta has executed a Master Services Agreement (MSA) establishing Cell Therapies Pty Ltd (CTPL), Australia's leading contract manufacturer of cell and gene therapies, as AdAlta’s preferred manufacturing partner of cellular immunotherapies. This agreement provides AdCella, AdAlta’s cellular immunotherapy collaboration with SYNthesis BioVentures (SYNBV), with key product development, manufacturing and supply chain capabilities. CTPL will support AdCella in delivering AdCella’s objective of providing innovative cellular immunotherapies originating in Asia with access to AdAlta’s i‑body® technology and a pathway to western regulated markets.